Document is current
Any future updates will be listed below
-
Authors
Kato, Tadashi
Yamashita, Mayu
Yasuda, Masahiro
Ando, Yutaro
Nakatsuka, Ryusuke
Shirouzu, Yasumasa
Fujioka, Tatsuya
Tsukasaki, Masayuki
Hattori, Fumiyuki
Taniyama, Yoshihiro
Ogata, Hiroaki
Sakashita, Akiko
Honda, Hirokazu
Hitomi, Hirofumi
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (25K11550)
Japan Society for the Promotion of Science (20K08598)
Japan Society for the Promotion of Science (21K08292)
Baxter Healthcare Corporation as an investigator-initiated research (IIR) program,
Kansai Medical University Molecular Imaging Center of Diseases
Katano Alumni Research Grant
Sanju Alumni Research Grant
- License Information
-
More Information
Article History
Received: 5 November 2025
Accepted: 20 April 2026
First Online: 25 April 2026
Declarations
:
: Commercially available human induced pluripotent stem cells (hiPSCs) were used in this study. The hiPSC lines 585A1 and 201B7-Ff were obtained from the RIKEN BioResource Research Center (BRC, Tsukuba, Japan). These cell lines were originally established from human donors with appropriate ethical approval and written informed consent at the source institution, as previously reported [ ] and in accordance with the guidelines of RIKEN BRC ( ). The cell lines were provided through the National BioResource Project and used under the conditions specified by RIKEN BRC. Because no donor-identifiable information was involved and no human materials were collected directly by the investigators, specific institutional ethics approval for human participants was not required according to the policy of Showa Medical University. All animal experiments were approved by the Showa Medical University Animal Experiment Committee (Approval No. 125015) and conducted in accordance with institutional and national guidelines.
: The authors declare no competing interests.
